PMCB - PharmaCyte Biotech gains on implementing second $10M share repurchase plan
- PharmaCyte Biotech ( NASDAQ: PMCB ) has authorized a second share repurchase program to repurchase up to $10M of it’s outstanding common stock.
- This share repurchase authorization is effective immediately for a two-year period.
- The company expects to fund the program with its available cash.
- The company enacted a similar program in June 2022 .
- Shares are trading up 3.46% premarket.
For further details see:
PharmaCyte Biotech gains on implementing second $10M share repurchase plan